Holen Sie sich die Stockscreener-App
49.51
1.71%
0.83
Schlusskurs vom Vortag:
$48.68
Offen:
$49.84
24-Stunden-Volumen:
4.47M
Relative Volume:
0.92
Marktkapitalisierung:
$99.19B
Einnahmen:
$43.93B
Nettoeinkommen (Verlust:
$8.53B
KGV:
12.95
EPS:
3.824
Netto-Cashflow:
$5.74B
1W Leistung:
-2.44%
1M Leistung:
+2.78%
6M Leistung:
-5.35%
1J Leistung:
+5.48%
1-Tages-Spanne:
$49.25
$50.28
1-Wochen-Bereich:
$47.35
$51.25
52-Wochen-Spanne:
$45.80
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
49.51 | 99.19B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-09-15 | Hochstufung | Berenberg | Hold → Buy |
| 2026-09-09 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-07-24 | Eingeleitet | Citigroup | Neutral |
| 2026-07-06 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth - Zacks Investment Research
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research
GSK (GSK) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China - GlobeNewswire Inc.
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer - GlobeNewswire Inc.
GSK plc (GSK) Stock Climbs 2.40% to $49.02, Positioned Evenly Between Support and ResistanceEarnings Beat Stocks - dars.gov.et
GSK plc (GSK) Stock Climbs 2.40% to $49.02, Positioned Evenly Between Support and ResistanceWave Alternation - https://www.siam.in/
Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire? - The Motley Fool
At £17.3550 per ordinary share, dividend reinvestment adds to GSK (GSK) executives’ interests. - Stock Titan
Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market Does - The Motley Fool
Call options on 1.5M shares feature in a passive Silence Therapeutics (SLN) stake. - Stock Titan
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dividend reinvestment brings GSK (NYSE: GSK) CEO Luke Miels 23.331 ordinary shares. - Stock Titan
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire Inc.
SGIOY Stock Price, Quote & News - Syfe
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies - GlobeNewswire Inc.
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.
Form 13D/A Opera Limited For: 24 September By Investing.com - Investing.com UK
GSK (NYSE: GSK) board members are buying company stock - Stock Titan
HSBC sets exchange rates for second interim dividend By Investing.com - Investing.com UK
Renalytix rises 7% as UBS holding grows and CEO buys shares - Yahoo Finance UK
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Australia
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Zacks Investment Research - גלובס
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView
GSK stock holds steady as investors weigh recent earnings and dividend - ad-hoc-news.de
BNTX Stock Price, Quote & News - Syfe
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - sahmcapital.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingGrowth Acceleration Report - careplusvn.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingEarnings Decline Risk - dars.gov.et
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingOne-Time Gain Impact - www.dars.gov.et
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingEPS Growth Report - https://www.dars.gov.et/
Resilient GSK stock holds firm as FDA and Japan clear key drugs - ad-hoc-news.de
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayProfit Cycle Analysis - careplusvn.com
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayRevenue Breakdown Analysis - dars.gov.et
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayEarnings Power Value - dars.gov.et
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayCEO Earnings Statement - https://www.dars.gov.et/
GSK (GSK) Latest: Ends Higher by 2.35% at $52.35 at the Close; Market Levels: $49.73 and $54.97 Define the Nearby Reference Levels at the CloseVolume Weighted Price - careplusvn.com
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gsk Plc Adr-Aktie (GSK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GSK plc | 10% Owner |
Dec 11 '25 |
Buy |
19.00 |
1,470,000 |
27,930,000 |
18,245,691 |
2.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):